Cannabis flower extracts as a multi-target agent in Alzheimer’s disease: Inhibition of AChE, BChE, and BACE1 with cell-protective effects in a PC12 cell model

Whole cannabis flower extracts inhibited three Alzheimer’s-related enzymes and improved cell viability under oxidative stress in laboratory experiments. The researchers studied multi-component extracts containing diverse cannabis compounds, examining their ability to act on several disease-related targets.

The extracts inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), enzymes that break down acetylcholine, a chemical messenger important for memory. They also inhibited BACE1, an enzyme involved in producing amyloid-beta. Cholinesterase inhibition exceeded that of galantamine under the tested assay conditions, with activity depending on extract composition.

Researchers also tested the extracts in PC12 cells exposed to hydrogen peroxide and amyloid-beta, finding improved viability under oxidative stress. Together, these findings identify whole cannabis flower extracts as promising candidates for investigating combined enzyme-inhibiting and cell-protective approaches to Alzheimer’s disease.

“Alzheimer’s disease (AD) is a neurodegenerative disorder marked by progressive cognitive decline. Despite extensive research, its multifactorial nature continues to challenge the development of effective therapies. Current treatments, including anticholinergic agents and amyloid β-targeted drugs, alleviate symptoms but fail to halt disease progression and often produce side effects. Therefore, novel multi-target strategies are urgently needed.

Cannabis (Cannabis sativa L.) has long been recognized for its medicinal properties, yet its potential in AD therapy has only recently gained attention. Previous studies have mainly focused on single cannabinoids or endocannabinoid system modulation.

In this study, we investigated whole cannabis flower extracts, rich in diverse active compounds, for their ability to inhibit key AD-related enzymes: acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and β-secretase (BACE1), using spectrophotometric assays.

Fractionation of one extract further identified components with potent inhibitory activity against both BChE and BACE1. Additionally, the extracts were evaluated for their cell-protective potential in PC12 cells exposed to hydrogen peroxide (H₂O₂) and amyloid β (Aβ₁-₄₂), mimicking AD-like oxidative stress conditions.

Cannabis extracts showed stronger inhibition of cholinergic enzymes compared to Galantamine, with efficacy depending on extract composition. Importantly, this study is among the first to reveal significant BACE1 inhibition by cannabis extracts. Moreover, the extracts enhanced PC12 cell viability under oxidative stress, indicating cell-protective effects.

Overall, these findings suggest that multi-component cannabis extracts may interact with several AD-related molecular targets in vitro and may serve as promising leads for further mechanistic and preclinical investigation.”

https://pubmed.ncbi.nlm.nih.gov/42934778

“Taken together, the study highlights the promise of cannabis inflorescence extracts, especially from Type II and III chemovars and fractions, as promising in-vitro multi-target candidates for further investigation in AD related models. By combining cholinesterase inhibition, BACE1 inhibition, and neuroprotection against oxidative and amyloid stress, cannabis-derived compounds may offer a more comprehensive approach compared to current single-target drugs.”

https://link.springer.com/article/10.1186/s42238-026-00479-9

Semi-Synthesis and Evaluation of Cannabichromene-Derived Amine and Amide Analogues as Anticancer Agents

Chemically modified compounds derived from cannabichromene (CBC), a cannabinoid found in cannabis, inhibited growth across multiple human cancer cell types in laboratory testing. Researchers synthesized a series of amine and amide analogues—modified versions of CBC—and screened them against the National Cancer Institute’s NCI-60 tumor cell panel.

Compounds 8 and 9 showed the strongest and broadest activity among the derivatives tested. Compound 9 was particularly active against PC-3 and DU-145 prostate cancer cells, inhibiting growth at low micromolar concentrations. It also induced apoptosis, the process of programmed cell death, in both prostate cancer cell lines.

The findings identify compound 9 as a promising starting point for further anticancer drug development. They highlight how CBC’s chemical structure can support the design of biologically active molecules, with further optimization and investigation needed to establish how these derivatives work.

“A novel series of cannabichromene-derived amine and amide analogues (4-13) was synthesized and evaluated for their anticancer activity against the NCI-60 human tumor cell line panel.

Among the synthesized derivatives, compounds 8 and 9 demonstrated the most potent and broad-spectrum anticancer activities, exhibiting significant percent growth inhibition across multiple cancer subtypes. Notably, compound 9 displayed good potency in prostate cancer cell lines PC-3 and DU-145, with GI50 values of 2.01 μM and 1.86 μM, respectively and pronounced cytotoxicity at higher concentrations. Its consistent performance across diverse cancer panels suggests a non-selective yet potent mechanism, likely targeting essential cellular pathways common to malignant cells. Compound 9 was found to induce apoptosis in PC-3 and DU-145 cells.

Collectively, these findings highlight 9 as a promising compound for further optimization and mechanistic exploration towards developing new anticancer leads derived from the cannabichromene scaffold.”

https://pubmed.ncbi.nlm.nih.gov/42924954

“In summary, the CBC amide analogues, particularly compounds 8 and 9, demonstrated significant anticancer potential across multiple NCI-60 cancer cell lines, exhibiting broad-spectrum cytotoxic activity.”

https://pubs.acs.org/jnprdf/article/89/10/2827/5442683/Semi-Synthesis-and-Evaluation-of-Cannabichromene

Hemp seed oil ameliorates DSS-induced ulcerative colitis in mice by altering transcriptomics and metabolomics

Hemp seed oil reduced disease activity, lowered inflammatory cytokines, and improved colon tissue findings in mice with experimentally induced ulcerative colitis. Researchers combined gene-expression and metabolic analyses to investigate how the oil influenced inflammation and intestinal protection.

Treatment suppressed IL-6, IL-1β, and IL-17, while gene-expression analysis indicated reduced IL-17 and TNF inflammatory signaling. It also increased expression of ZO-1 and occludin, proteins that help maintain the intestinal barrier by keeping neighboring cells tightly connected.

Researchers identified 19 altered colon metabolites associated with amino acid metabolism, energy balance, and lipid signaling. These preclinical findings suggest that hemp seed oil acts on interconnected metabolic and inflammatory processes, supporting further investigation of its therapeutic potential for inflammatory bowel disease.

“Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease with complex pathogenesis and limited treatments.

Hemp seed oil, with its unique ω-6/ω-3 polyunsaturated fatty acid ratio and phenolic antioxidants, exhibits anti-inflammatory and gut barrier-enhancing properties, though its mechanisms in UC are not fully understood.

Here, we applied an integrated transcriptomics and metabolomics approach to investigate the effects of hemp seed oil in dextran sulfate sodium (DSS)-induced UC mice.

Treatment with hemp seed oil (1 g/kg) significantly alleviated disease activity, suppressed proinflammatory cytokine levels (interleukin (IL)-6, IL-1β, and IL-17), and improved colonic histopathology. Metabolomic profiling via ultrahigh-performance liquid chromatography-quadrupole-orbitrap tandem mass spectrometry (UPLC-Q-Orbitrap MS/MS) identified 19 significantly altered colonic metabolites, predominantly involved in amino acid metabolism, energy homeostasis, and lipid signalling pathways.

Transcriptomic analysis suggested that hemp seed oil treatment was associated with inhibition of the IL-17 and tumor necrosis factor (TNF) signalling pathways while upregulating genes involved in barrier function (e.g., zonula occludens-1 (ZO-1) and Occludin). Integrative analysis revealed strong inverse correlations between key metabolites (e.g., docosahexaenoic acid ethyl ester, adenosine diphosphate (ADP)) and IL-17 pathway activation (IL17A, C-X-C motif chemokine ligand 10 (CXCL10)), suggesting that hemp seed oil may attenuate UC through reprogramming the “metabolism‒inflammation” axis.

These findings suggest potential multitarget therapeutic mechanisms of hemp seed oil against UC, indicate critical links between metabolic reprogramming and the immune‒inflammatory axis, and offer novel insights for the development of phytomedicine for the treatment of inflammatory bowel disease.”

https://pubmed.ncbi.nlm.nih.gov/42766258/

https://link.springer.com/article/10.1007/s11418-026-02082-x

Cannabis sativa phytoligands as potential EGFR inhibitors for lung cancer treatment

Compounds found in Cannabis sativa showed promising predicted binding to epidermal growth factor receptor (EGFR), a protein that promotes tumour-cell proliferation when overexpressed. Using computer-based screening, researchers identified luteolin-7-O-glucoside, grossamide, and quercetin as leading candidates for blocking the receptor’s kinase domain—a target in lung cancer treatment.

During 100-nanosecond molecular dynamics simulations, quercetin formed the most structurally stable EGFR complex. Grossamide produced the most favourable calculated binding free energy, exceeding the reference drug gefitinib in this computational measure. The leading compounds also showed favourable predicted pharmacokinetic profiles.

These findings highlight cannabis plant compounds as candidates for developing therapies that target EGFR.

“Lung cancer remains a major global health burden, and epidermal growth factor receptor (EGFR) overexpression promotes tumour-cell proliferation, making EGFR an important therapeutic target.

This study used an in-silico approach to evaluate Cannabis sativa compounds as inhibitors of the EGFR kinase domain.

Among the compounds investigated, Luteolin-7 -O- glucoside, grossamide, and quercetin were the leading ATP-competitive inhibitors, with binding affinities of -10.878, -10.091, and – 10.000 kcal/mol, respectively. A four-feature pharmacophore model was generated from the lead compounds, which also showed favourable predicted pharmacokinetic profiles.

During 100-ns molecular dynamics simulations (MDS), the EGFR-quercetin complex exhibited the lowest root mean square deviation of 0.9-1.5 Å, while fluctuation profiles revealed a relatively stable ligand-bound complex compared with the apo-EGFR. The MDS trajectory Molecular Mechanics/Generalized Born Surface Area analysis yielded binding free energies of -75.59 kcal/mol for grossamide, -56.90 kcal/mol for isovitexin, -49.11 kcal/mol for luteolin-7 -O- glucoside, and – 43.27 kcal/mol for quercetin, compared with – 47.41 kcal/mol for gefitinib. Electronic profiling revealed favourable orbital overlap and softness for quercetin and flavone glycosides within EGFR, while isovitexin showed superior kinetic stability and balanced solvation, supporting strong binding and active-site entry.

These findings identify luteolin-7 -O- glucoside, grossamide, and quercetin as promising EGFR inhibitors and provide a baseline hypothesis for experimental validation.”

https://pubmed.ncbi.nlm.nih.gov/42999331

https://www.researchsquare.com/article/rs-11024152/v1

Direct evidence for psychoactive cannabis use 2800 years ago

Chemical traces in human hair from a burial mound in southern Siberia provide the oldest directly dated evidence that people used cannabis for its mind-altering effects. The findings, published in Science, place psychoactive cannabis use at least 2,800 years ago.

At the Tunnug 1 burial mound, researchers radiocarbon-dated six cannabis seeds, placing them in the early eighth century BCE. High-resolution mass spectrometry detected clear signals consistent with cannabinol (CBN), which can form as THC oxidizes, in several hair samples. The researchers also found weaker signals consistent with THC itself.

The seeds establish that cannabis was placed in the tomb. The chemical traces in the hair are what led researchers to conclude that people likely used it for its psychoactive effects. The analysis leaves open how much they used and whether they inhaled or ingested it.

“Cannabis is the world’s most-used illicit psychoactive plant, yet direct prehistoric evidence for its consumption is rare. In this study, we present the earliest direct evidence of cannabis use: offerings of plant parts and chemical compounds in ancient human hair recovered from a monumental tomb in Siberia.

The findings suggest that the plant was used for its psychoactive qualities across Eurasia, where specific wild populations might have had naturally higher active compound levels. We show that the practice of cannabis consumption dates back at least 2800 years, anchoring debates around contemporary usage and informing discussions on cannabis in medicine, public health, law, and industry.”

https://pubmed.ncbi.nlm.nih.gov/42986939

“Psychoactive plants are used globally today, with increasing evidence of medicinal value and, in some cases, decreasing illegality. Cannabis is one of the most widely used and cultivated of these plants. The prevalence of past usage, particularly for ritual purposes, has often been suggested, but making conclusions about its use for psychoactive properties has been difficult. Cannabis plants are ephemeral, and even the presence of plant parts and seeds could be an indication of cultivation for its many other useful properties. Caspari et al. found cannabis plant parts in a 2800-year-old tomb in Siberia and also identified its psychoactive compounds in hair found within the tomb, suggesting ritualistic psychoactive use.”

https://www.science.org/doi/10.1126/science.aeg3800

Efficacy of dietary hempseed oil in patients with atopic dermatitis

Dietary hempseed oil improved skin dryness and itching and reduced the use of skin medications in patients with atopic dermatitis, commonly called eczema. Researchers compared hempseed oil with olive oil in a 20-week randomized, single-blind crossover trial, examining symptoms, blood fatty acid profiles, and moisture loss through the skin.

After hempseed oil consumption, blood levels of linoleic acid, alpha-linolenic acid, and gamma-linolenic acid increased. Patients reported significant improvements in dryness and itching, along with reduced medication use. Skin moisture loss also decreased, although that change did not reach statistical significance.

The authors suggested that the symptom improvements resulted from hempseed oil’s abundant, balanced supply of polyunsaturated fatty acids. These human clinical findings support the therapeutic potential of dietary hempseed oil for eczema and highlight the value of cannabis seeds beyond their basic nutritional benefits.

“Background: Hempseed oil is a rich and balanced source of omega-6 and omega-3 polyunsaturated fatty acids (PUFAs). Anecdotal evidence indicated that dietary hempseed oil might be useful in treating symptoms of atopic dermatitis.

Patients and methods: Dietary hempseed oil and olive oil were compared in a 20-week randomized, single-blind crossover study with atopic patients. Fatty acid profiles were measured in plasma triglyceride, cholesteryl and phospholipid fractions. A patient questionnaire provided additional information on skin dryness, itchiness and usage of dermal medications. Skin transepidermal water loss (TEWL) was also measured.

Results: Levels of both essential fatty acids (EFAs), linoleic acid (18:2n6) and alpha-linolenic acid (18:3n3), and gamma-linolenic acid (GLA; 18:3n6) increased in all lipid fractions after hempseed oil, with no significant increases of arachidonic acid (20:4n6) in any lipid fractions after either oil. Intra-group TEWL values decreased (p=0.074), qualities of both skin dryness and itchiness improved (p=0.027) and dermal medication usage decreased (p=0.024) after hempseed oil intervention.

Conclusions: Dietary hempseed oil caused significant changes in plasma fatty acid profiles and improved clinical symptoms of atopic dermatitis. It is suggested that these improvements resulted from the balanced and abundant supply of PUFAs in this hempseed oil.”

https://pubmed.ncbi.nlm.nih.gov/16019622

https://www.tandfonline.com/doi/abs/10.1080/09546630510035832

Optimal cannabinoid-terpene combination ratios suppress mutagenicity of gastric reflux in normal and metaplastic esophageal cells

Cannabigerol (CBG) paired with selected plant compounds reduced reflux-related DNA damage in laboratory models of the human esophagus. Researchers tested cannabinoid–terpene combinations in normal esophageal cells and Barrett’s esophagus cells, which represent changes associated with increased esophageal cancer risk.

A combination of CBG and phytol—a plant-derived terpenoid—at a 1:5 ratio showed particular promise. It reduced bile-acid-induced DNA damage and oxidative stress, helped maintain mitochondrial function, and encouraged damaged cells to undergo programmed cell death. The researchers also reported reduced mutagenicity, suggesting protection against changes that can contribute to cancer development.

These findings identify cannabinoid–terpene ratios worth investigating for protection against reflux-related cellular injury. The results come from cell experiments; animal studies and clinical trials are needed to determine whether these combinations could benefit people with reflux or Barrett’s esophagus.

“Background: Esophageal adenocarcinoma (EAC) frequently arises from chronic exposure to acid and bile reflux, with secondary bile acids, such as deoxycholic acid (DCA), contributing to its pathogenesis through mechanisms involving reactive oxygen species (ROS), oxidative DNA damage, and resistance to apoptosis. The human endocannabinoid system (ECS) regulates diverse anti-inflammatory, antioxidant, and analgesic pathways implicated in disease modulation and may counteract the harmful effects of gastroesophageal reflux. Despite its therapeutic promise, effective pharmacological activation of the ECS remains challenging.

Aim: To evaluate whether specific cannabinoid-terpene combinations targeting the ECS could attenuate the mutagenic and cytotoxic effects of bile acid-induced stress in esophageal cell models, and to assess the clinical significance of ECS-related protein receptors in the progression of EAC.

Methods: Human esophageal epithelial cells exposed to DCA, as well as a Barrett’s esophagus cell line subjected to low potential of hydrogen and a bile acid cocktail, were treated with various ratios of phyto-cannabinoids and terpenes. Endpoints included DNA damage, mitochondrial membrane potential, and ROS production to identify optimal compound combinations. Expression of ECS-related receptor proteins in clinical samples was assessed by immunohistochemistry.

Results: A 1:5 ratio of cannabigerol to phytol significantly reduced DCA-induced DNA damage, preserved mitochondrial membrane potential, and decreased ROS levels. This combination also promoted apoptosis in damaged cells and reduced mutagenicity. Analysis of patient samples demonstrated that expression of the ECS-associated receptor protein CB1 correlated with EAC progression, indicating a broader clinical role for ECS modulation in cancer prevention.

Conclusion: Modulation of the ECS using systematically selected cannabinoid-terpene ratios can attenuate bile acid-induced esophageal damage and may reduce carcinogenic progression. These findings support further in vivo studies and raise the possibility of expanding cannabinoid-terpene therapeutics to other diseases with comparable pathogenic mechanisms.”

https://pubmed.ncbi.nlm.nih.gov/42829479

“The combination of CBG and terpenes may offer novel cancer prevention strategies to address the increasing incidence of esophageal cancer, a disease lacking effective treatment options.”

https://www.wjgnet.com/1007-9327/full/v32/i14/111455.htm

Hemp (Cannabis sativa L.) Seed Protein and Its Hydrolysate Promote Bone Formation via the SMAD-Dependent BMP Pathway

Hemp seed protein and its enzyme-derived peptides promoted bone formation in cell experiments and mouse models of osteoporosis. Researchers found that both preparations stimulated bone-forming cell development and mineral deposition, with the peptide preparation generally producing stronger effects.

These effects involved the SMAD-dependent BMP pathway, a signaling system that helps direct bone growth. Treatment increased bone-formation markers and improved the formation and mass of trabecular bone—the supportive, spongy structure inside bones—in aging and ovariectomy-induced osteoporosis models.

The researchers also incorporated hemp seed peptides into stem-cell-containing organoids, which supported mineralization and accelerated repair after implantation into skull-bone defects in mice. These preclinical findings identify hemp seed proteins and peptides as promising candidates for developing treatments for osteoporosis and bone repair.

“Objective

With the global increase in aging populations, the prevalence of osteoporosis is rising. Current preventive and therapeutic strategies remain limited. The present study aimed to investigate the effects of hemp seed protein (HSP) and its hydrolysis-derived bioactive peptides (HPH) on osteogenic differentiation and to elucidate their therapeutic potential for osteoporosis.

Methods

The osteogenic differentiation of mouse pre-osteoblast MC3T3-E1 cells and human mesenchymal stem cells (hMSCs) was assessed by means of alkaline phosphatase (ALP) staining, alizarin red S (ARS) staining, and RT-qPCR. The screening of signaling pathways was conducted through the implementation of luciferase reporter assays. The in vivo efficacy of the treatment was evaluated in aging and ovariectomy (OVX)-induced osteoporotic mice using calcein labeling and micro-CT. Furthermore, hMSCs encapsulated in HPH-loaded hyaluronic acid methacrylate (HAMA) hydrogel were combined with trabeculae-like biomimetic bone-filling material (TBM) to generate organoids for in vitro culture or calvarial implantation, thereby enabling the evaluation of the in situ osteogenic capacity of HPH.

Results

HSP and HPH enhanced ALP activity, mineralization, and osteogenic gene expression (ALP, RUNX2). Mechanistically, they activated SMAD4 and BMP2/BMP4 expression while suppressing SMAD2, indicating SMAD-dependent BMP pathway involvement. In the mouse models of osteoporosis, the administration of HSP/HPH was found to augment both the mineral apposition rate (MAR) and the trabecular bone mass. In organoid models, HPH was found to maintain cell viability, upregulate ALP and RUNX2 expression, and promote mineralization in vitro. Furthermore, upon calvarial implantation, HPH-loaded organoids were found to accelerate bone defect repair.

Conclusion

These findings indicate that HSP and HPH promote osteogenesis via the SMAD-dependent BMP pathway. The organoid results further demonstrate the in situ osteogenic potential of HPH, supporting its translational applications. HSP and HPH have demonstrated therapeutic potential in the treatment of osteoporosis and bone defects, providing novel approaches for disease management.”

https://onlinelibrary.wiley.com/doi/full/10.1002/inm3.70066

Cannabidiol in Adults With Lennox-Gastaut Syndrome: Real-World Experience

Cannabidiol (CBD) added to existing treatment was associated with sustained seizure reductions in adults with Lennox–Gastaut syndrome (LGS), a severe form of epilepsy involving multiple seizure types. In this 79-person clinical review, approximately two-thirds achieved at least a 50% reduction in overall seizures at their last follow-up.

Researchers reviewed clinical records and caregiver seizure diaries over a median follow-up of 41 months. Seizure-free days increased from 5.7 to 12.5 per month, while seizure-related hospital admissions and injuries declined. Caregivers also reported cognitive or behavioral improvements in 48 patients.

CBD is a naturally occurring, non-intoxicating cannabinoid found in Cannabis sativa. These findings support its use as an add-on treatment for adults with LGS. Drowsiness and diarrhea were common, and medication adjustments were often needed to manage side effects and interactions; 14 patients were able to discontinue one or more other antiseizure medications.

“Background: We report a single centre experience of cannabidiol use as adjunctive treatment in adults with Lennox-Gastaut Syndrome (LGS).

Methods: Retrospective review of adults with LGS treated with cannabidiol with clinical data collected from electronic records and caregiver standardised seizure diaries with seizure-related outcomes assessed at baseline, 6 months, and last follow-up.

Results: Seventy-nine adults (median age 29 years; 40 male) were included. Median follow-up was 41 months. Four patients died unrelated to cannabidiol treatment. Sixty-seven (86%) remained on treatment at last follow-up. Across all seizure types, 59.5% achieved ≥ 50% reduction at 6 months and 67.1% at last follow-up. Among those with ‘Drop Seizures’ (n = 78), 50% achieved > 50% reduction at 6 months and 61.5% at last follow-up. ‘Drop Seizure’ responder rates were numerically higher with clobazam > 5 mg/day, but with no statistically significant dose-response relationship seen. Seizure-free days increased (baseline 5.7/month; last follow-up 12.5/month). Seizure-related hospital admissions and injuries declined. Cognitive or behavioural improvements were reported in 48 patients (60.8%); there was no statistically significant association with achieving ≥ 50% seizure reduction. Drowsiness (n = 33) was the most frequent adverse event often related to drug-drug interactions. Diarrhoea (n = 24) was more common than previously reported. Side-effects necessitated ASM adjustments in 51 patients. Fourteen were able to withdraw one or more ASMs.

Conclusions: CBD was associated with sustained effectiveness and good tolerability in adults with LGS, with high retention and improvement in seizure and other clinically meaningful outcomes. Adverse effects, mainly interaction-related, were usually managed with concomitant medication adjustments.”

https://pubmed.ncbi.nlm.nih.gov/42798297

“Cannabidiol was associated with a significant reduction in seizure burden, increased seizure-free days, and reduced need for emergency care, alongside high treatment retention and manageable side effects, which resolved with dose adjustments. Improvements in caregiver-reported cognitive and behavioural function were also noted. These findings underscore the utility of cannabidiol as an effective and well-tolerated adjunctive therapy in adult patients with LGS and highlight its potential role in rationalising complex ASM regimens.”

https://onlinelibrary.wiley.com/doi/10.1111/ene.70760

Cannabis in cancer: a review of therapeutic potential, clinical and preclinical status, and legislation

Cannabinoids show consistent antitumor activity in cell and animal studies, according to this review examining cannabis in cancer care. The authors assess effects on tumor growth, blood-vessel formation, cancer spread, and immune regulation, alongside findings from human clinical studies.

The review highlights a gap between experimental results and established clinical applications. Approved cannabis-based medicines primarily address symptoms and treatment-related problems, including chemotherapy-associated nausea and vomiting, while their potential to directly control cancer requires further clinical evaluation.

Differences in dosing, formulations, study methods, and national laws complicate the development of cannabinoid therapies. By examining both the science and legislation across Western and Asian countries, the review identifies more consistent research practices and coordinated regulation as important steps toward translating promising findings into clinical care.

“The involvement of cannabis and cannabinoid-based products in the inhibition or progression of cancer has been reported in previous studies. However, only a limited number of cannabis-based products have been approved for specific clinical indications.

This review critically evaluates the therapeutic potential of cannabis and cannabinoid-based products in cancer, with particular emphasis on the consistency between preclinical evidence and clinical outcomes. Cannabinoids were systematically evaluated across available cell-based and animal model studies, as well as clinical studies to assess their regulatory effects on tumor growth, angiogenesis, metastasis, and immune modulation.

Although preclinical studies demonstrate consistent antitumor activity, currently approved cannabis-based products are largely restricted to palliative indications, such as pain relief and management of chemotherapy-related symptoms, rather than disease-modifying cancer therapies. Furthermore, substantial variability in study design, dosing, formulation, and regulatory constraints hampers the translation of experimental findings into clinical practice.

This review provides a comprehensive clinical assessment of cannabis and cannabinoid-based products in the treatment of various cancers and examines the regulatory and legal frameworks governing their use in Western and Asian countries.

Despite the increasing global trend toward the legalization of medical cannabis, the lack of legislative harmonization remains a major barrier to the development, distribution, and clinical implementation of cannabis-based products.”

https://pubmed.ncbi.nlm.nih.gov/42836893

https://link.springer.com/article/10.1007/s12272-026-01631-y